Published in J Immunol on October 01, 2007
Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (2009) 2.52
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother (2011) 1.46
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J (2012) 1.26
Biomimetic delivery with micro- and nanoparticles. Adv Mater (2012) 1.25
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev (2014) 1.14
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A (2016) 1.09
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2010) 1.06
Genetic engineering of T cells for adoptive immunotherapy. Immunol Res (2008) 1.05
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One (2010) 1.02
Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res (2008) 1.02
Cancer vaccine by fusions of dendritic and cancer cells. Clin Dev Immunol (2010) 1.00
Artificial antigen-presenting cells for use in adoptive immunotherapy. Cancer J (2010) 1.00
Dynamic regulation of functionally distinct virus-specific T cells. Proc Natl Acad Sci U S A (2010) 0.99
Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother (2011) 0.98
Immune regulatory antibodies: are they the next advance? Cancer J (2010) 0.97
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res (2016) 0.95
Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. J Mol Biol (2008) 0.94
Stem cell-based anti-HIV gene therapy. Virology (2011) 0.94
Driving gene-engineered T cell immunotherapy of cancer. Cell Res (2016) 0.89
Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel) (2015) 0.89
Predicting cytotoxic T-cell age from multivariate analysis of static and dynamic biomarkers. Mol Cell Proteomics (2010) 0.88
Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells. J Immunol (2012) 0.87
Finding Balance: T cell Regulatory Receptor Expression during Aging. Aging Dis (2011) 0.86
Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer (2013) 0.85
Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. J Immunol (2008) 0.83
Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J (2008) 0.82
T-cell artificial focal triggering tools: linking surface interactions with cell response. PLoS One (2009) 0.81
Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother (2011) 0.81
Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. J Transl Med (2013) 0.81
Linking form to function: Biophysical aspects of artificial antigen presenting cell design. Biochim Biophys Acta (2014) 0.81
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Immune checkpoint blockade and interferon-α in melanoma. Semin Oncol (2015) 0.77
Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy. PLoS One (2016) 0.76
Human T cell crosstalk is induced by tumor membrane transfer. PLoS One (2015) 0.76
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. J Immunol Res (2016) 0.76
Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. PLoS One (2016) 0.76
Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy. J Biomed Biotechnol (2010) 0.76
Monosomy 1p36 uncovers a role for OX40 in survival of activated CD4+ T cells. Clin Immunol (2008) 0.75
Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy. J Immunol Res (2015) 0.75
Costimulatory molecules as vaccine adjuvants: to 4-1BB or not to 4-1BB? Cell Mol Immunol (2014) 0.75
The use of immunotherapy in the treatment of melanoma. J Hematol Oncol (2017) 0.75
Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS One (2014) 0.75
Artificial antigen-presenting cells expressing AFP158-166 peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes. Oncotarget (2016) 0.75
Transient stimulation expands superior antitumor T cells for adoptive therapy. JCI Insight (2017) 0.75
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 14.39
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 11.04
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell (1994) 9.25
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04
Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med (2004) 5.49
Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol (2001) 5.48
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol (2003) 5.01
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood (2004) 4.01
CD28- T lymphocytes. Antigenic and functional properties. J Immunol (1993) 3.67
Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 3.63
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther (2007) 2.99
Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol (1997) 2.98
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol (1993) 2.40
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood (2003) 2.27
Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med (2003) 2.21
Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol (1999) 1.95
4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol (2001) 1.90
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol (2005) 1.85
Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol (1993) 1.81
Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol (2000) 1.67
Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol (1997) 1.62
Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol (1997) 1.59
IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol (2006) 1.58
4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol (1994) 1.58
Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther (2003) 1.53
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood (2002) 1.40
Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 1.27
A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol (2002) 1.26
CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol (1999) 1.19
Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood (2001) 1.16
Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. Clin Immunol (2000) 1.16
Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood (2001) 1.03
Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood (2003) 0.97
B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Eur J Immunol (1997) 0.94
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res (2005) 0.90
HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol (2005) 0.85
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 6.65
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med (2007) 5.24
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol (2005) 3.51
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 3.48
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
Interleukin-7: from bench to clinic. Blood (2002) 3.01
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med (2005) 3.01
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther (2007) 2.99
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 2.86
CARs on track in the clinic. Mol Ther (2011) 2.86
Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest (2005) 2.84
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
A role for thymic stromal lymphopoietin in CD4(+) T cell development. J Exp Med (2004) 2.81
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood (2004) 2.63
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest (2005) 2.48
The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med (2010) 2.40
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood (2005) 2.39
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood (2004) 2.33
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci U S A (2002) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood (2002) 2.31
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood (2004) 2.28
Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst (2002) 2.24
Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med (2003) 2.21
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol (2003) 2.09
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. Hum Pathol (2013) 2.06
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med (2011) 2.04
Autoimmunity during lymphopenia: a two-hit model. Clin Immunol (2006) 2.01
Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol (2009) 1.98
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther (2009) 1.97
Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87
CD28 costimulation is essential for human T regulatory expansion and function. J Immunol (2008) 1.86
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood (2013) 1.85
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther (2002) 1.83
Side population keratinocytes resembling bone marrow side population stem cells are distinct from label-retaining keratinocyte stem cells. J Invest Dermatol (2003) 1.83
Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther (2004) 1.80
Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood (2013) 1.80
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol (2008) 1.71
Cdc42-interacting protein-4 functionally links actin and microtubule networks at the cytolytic NK cell immunological synapse. J Exp Med (2007) 1.70
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood (2012) 1.64
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood (2014) 1.64
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res (2011) 1.62
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 1.57
Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest (2009) 1.54
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res (2011) 1.53
Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther (2003) 1.53
Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediatr Blood Cancer (2011) 1.53
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev (2015) 1.53
Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol (2010) 1.51
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50
CCL2 blockade augments cancer immunotherapy. Cancer Res (2009) 1.48
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98. J Immunol (2010) 1.48